Dr Reddy’s Laboratories (DRL) has launched Zenatane (Isotretinoin Capsules USP) in 20 mg and 40 mg, a therapeutically equivalent generic version of Accutane (Isotretinoin Capsules USP) in the US market following the approval by the United States Food & Drug Administration (US FDA) of DRL’s ANDA for Zenatane 10 mg, 20 mg and 40 mg.
The total market had US sales of approximately $309 million for the most recent twelve months ending January 2013 according to IMS Health.
Dr Reddy’s Zenatane Capsules 10 mg, 20 mg, & 40 mg will be available in boxes of 30 (3 prescription packs of 10 capsules), as unit dose blisters.
EP News Bureau – Mumbai